Waldenström's macroglobulinemia (WM) is increasingly being associated with amyloidosis particularly of the amyloid light-chain variety. We report on one of the few cases of WM associated with serum amyloid A protein (AA) amyloidosis. Autologous stem cell transplant (ASCT) is now being increasingly used for the treatment of amyloidosis, but most studies are small case series. Traditionally AA amyloid is associated with connective tissue disorders and periodic fever syndromes and has been treated by addressing the underlying condition. We present the first case of serum amyloid A being treated with melphalan-based ASCT to deal with the underlying WM and thereby control the amyloid, thus demonstrating the viability of this novel approach for the treatment of this disorder.

Treon SP: How I treat Waldenstrom's macroglobulinemia. Blood 2009;117:2918-2923.
Terrier B, Jaccard A, Harousseau JL, Delarue R, Tournilhac O, Hunault-Berger M, Hamidou M, Dantal J, Bernard M, Grosbois B, Morel P, Coiteux V, Gisserot O, Rodon P, Hot A, Elie C, Leblond V, Fermand JP, Fakhouri F: The clinical spectrum of IgM-related amyloidosis. A French nationwide retrospective study of 72 patients. Medicine 2008;87:99-109.
Gertz MA, Kyle RA, Noel P: Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom's macroglobulinemia. J Clin Oncol 1993;11:914-920.
Wechalekar AD, Lachmann HJ, Goodman HJB, Bradwell A, Hawkins PN, Gillmore JD: AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood 2008;112:4009-4016.
Tatara R, Nagai T, Kobayashi H, Hatano K, Suzuki T, Muroi K, Ozawa K: AA amyloidosis associated with macroglobulinemia. Int J Hematol 2010;92:675-677.
Gardyn J, Schwartz A, Gal R, Lewinski U, Kristt D, Cohen AM: Waldenstrom's macroglobulinemia associated with AA amyloidosis. Int J Hematol 2001;74:76-78.
Moyner K, Sletten K, Husby G, Natvig JB: An unusually large (83 amino acid residues) amyloid fibril protein AA from a patient with Waldenstrom's macroglobulinemia and amyloidosis. Scand J Immunol 1980;11:549-554.
Ogami Y, Takasugi M, Soejima M, Kuroiwa A, Oma H, Nakano M, Haratake J, Toyoshima M, Watanabe T: Waldenstrom's macroglobulinemia associated with amyloidosis and crescentic glomerulonephritis. Nephron 1989;51:95-98.
Cornwell GG 3rd, Husby G, Westermark P, Natvig JB, Michaelsen TE, Skogen B: Identification and characterization of different amyloid fibril proteins in tissue sections. Scand J Immunol 1977;6:1071-1080.
Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN: Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-2371.
Valente M, Roy V, Lacy MQ, Dispenzieri A, Gertz MA: Autologous stem cell transplantation and IgM amyloidosis. Leuk Lymphoma 2006;47:1006-1012.
Schonland SO, Dreger P, de Witte T, Hegenbart U: Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. Bone Marrow Transplant 2012;47:895-905.
Ogita M, Hoshino J, Sogawa Y, Sawa N, Katori H, Takemoto F, Ubara Y, Hara S, Miyakoshi S, Takaichi K: Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Clin Nephrol 2007;68:171-176.
Obici L, Merlini G: AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly 2012;142:w13580.
Murphy CL, Eulitz M, Hrncic R, Sletten K, Westermark P, Williams T, Macy SD, Wooliver C, Wall J, Weiss DT, Solomon A: Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens. Am J Clin Pathol 2001;116:135-142.
Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR, Dogan A: Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009;114:4957-4959.
Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G: Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-328.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.